ERBB2 and non-small cell lung carcinoma: Based on the biology of this pathway in normal and disease processes, we sought to describe discrepancies in HER2 diagnostic assays that could potentially explain discordances in response to distinct classes of agents targeting HER2 in patients with NSCLC.